

24 November 2006

**Sent via email**

Dear Consultee/Commentator

### **Single Technology Appraisal**

#### **Cetuximab for the treatment of locally advanced squamous cell head and neck cancer**

As you are aware, the Appraisal Committee met to consider this appraisal on Thursday 9 November 2006.

At this meeting the Committee was presented with extra information on cetuximab in the treatment of locally advanced squamous cell head and neck cancer. Specifically, this information consisted of the scientific discussion published by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as part of the extension of the marketing authorisation for cetuximab. This scientific discussion is published on the EMA website as part of the European Public Assessment Report.

As a consequence of having been presented with this information at a late stage the Committee decided that it needed to further discuss the implications of the extra information in its next meeting which is planned for 11 January 2007.

I know that you will be disappointed with this extension of the timeline for this appraisal, but I hope you agree that the way forward outlined above will enable the development of a guidance which in the end will be appropriate for the NHS.

Thank you for your patience; if you have any questions or queries, please contact Mr Christopher Feinmann, Technology Appraisal Project Manager (email: [christopher.feinmann@nice.org.uk](mailto:christopher.feinmann@nice.org.uk) or ☎ 0161 209 3856).

Yours sincerely

**Meindert Boysen**  
**Associate Director STA**  
**Centre for Health Technology Evaluation**